Rat Models of Diet-Induced Obesity and High Fat/Low Dose Streptozotocin Type 2 Diabetes: Effect of Reversal of High Fat Diet Compared to Treatment with Enalapril or Menhaden Oil on Glucose Utilization and Neuropathic Endpoints

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Holmes, Amey ^a   Coppey, Lawrence J ^b   Davidson, Eric P ^b   Yorek, Mark A ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; MENHADEN OIL; STREPTOZOCIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIET INDUCED OBESITY; DRUG EFFECT; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; LIPID DIET; MALE; MOTOR NERVE CONDUCTION; NERVE FIBER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; STEATOSIS; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIET THERAPY; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECTS; LOW FAT DIET; NEURALGIA; NONALCOHOLIC FATTY LIVER; OBESITY; SPRAGUE DAWLEY RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-OBESITY AGENTS; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIET, FAT-RESTRICTED; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENALAPRIL; FISH OILS; HYPOGLYCEMIC AGENTS; MALE; NEURALGIA; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; WEIGHT LOSS;

EID: 84937020053     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/307285     Document Type: Article

References (42)

1. E.P. Davidson, L. J. Coppey, A. Holmes, and M. A. Yorek, "Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats," European Journal of Pharmacology, vol. 677, no. 1-3, pp. 180-187, 2012.
2. C. L. Oltman, E. P. Davidson, L. J. Coppey, T. L. Kleinschmidt, B. Dake, and M. A. Yorek, "Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats," European Journal of Pharmacology, vol. 650, no. 2-3, pp. 556-562, 2011.
3. L. Coppey, E. Davidson, B. Lu, C. Gerard, and M. Yorek, "Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesityand diabetes-induced neuropathy in C57Bl/6J mice," Neuropharmacology, vol. 60, no. 2-3, pp. 259-266, 2011.
4. M. A. Yorek, "The potential role of angiotensin converting enzyme and vasopeptidase inhibitors in the treatment of diabetic neuropathy," Current Drug Targets, vol. 9, no. 1, pp. 77-84, 2008.
5. L. J. Coppey, E. P. Davidson, T. W. Rinehart et al., "ACE inhibition or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats," Diabetes, vol. 55, no. 2, pp. 341-348, 2006.
6. S. M. Manschot, W.H. Gispen, L. J. Kappelle, and G. J. Biessels, "Nerve conduction velocity and evoked potential latencies in streptozotocin-diabetic rats: effects of treatment with an angiotensin converting enzyme inhibitor," Diabetes/Metabolism Research and Reviews, vol. 19, no. 6, pp. 469-477, 2003.
7. R. A. Malik, S. Williamson, C. Abbott et al., "Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial," The Lancet, vol. 352, no. 9145, pp. 1978-1981, 1998.
8. E. J. Henriksen and M. Prasannarong, "The role of the reninangiotensin system in the development of insulin resistance in skeletalmuscle," Molecular and Cellular Endocrinology, vol. 378, no. 1-2, pp. 15-22, 2013.
9. S. D. Premaratna, E. Manickam, D. P. Begg et al., "Angiotensin converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice," International Journal of Obesity, vol. 36, no. 2, pp. 233-243, 2012.
10. R. S. Weisinger, T. K. Stanley, D. P. Begg, H. S. Weisinger, K. J. Spark, and M. Jois, "Angiotensin converting enzyme inhibition lowers bodyweight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet," Physiology and Behavior, vol. 98, no. 1-2, pp. 192-197, 2009.
11. H.-Q. Liu, Y. Qiu, Y. Mu et al., "A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SDrats," Nutrition Research, vol. 33, no. 10, pp. 849-858, 2013.
12. S. Sarbolouki, M. H. Javanbakht, H. Derakhshanian et al., "Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetic mellitus patients: a doubleblind randomized clinical trial," Singapore Medical Journal, vol. 54, no. 7, pp. 387-390, 2013.
13. X. Liu, Y. Xue, C. Liu et al., "Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice," Lipids in Health and Disease, vol. 12, no. 1, article 109, 2013.
14. K. G. Lamping, D. W. Nuno, L. J. Coppey et al., "Modification of high saturated fat diet with n-3 polyunsaturated fat improves glucose intolerance and vascular dysfunction," Diabetes, Obesity and Metabolism, vol. 15, no. 2, pp. 144-152, 2013.
15. L. J. Coppey, E. P. Davidson, A. Obrosov, and M. A. Yorek, "Enriching the diet with menhaden oil improves peripheral neuropathy in streptozotocin-induced type 1 diabetic rats," Journal of Neurophysiology, vol. 113, no. 3, pp. 701-708, 2015.
16. T. C. Coste, A. Gerbi, P. Vague, G. Pieroni, and D. Raccah, "Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy," Diabetes, vol. 52, no. 10, pp. 2578-2585, 2003.
17. A. Gerbi, J.-M. Maixent, J.-L. Ansaldi et al., "Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats," Journal of Nutrition, vol. 129, no. 1, pp. 207-213, 1999.
18. E.P. Davidson, L. J. Coppey, N. A. Calcutt, C. L. Oltman, and M. A. Yorek, "Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction," Diabetes/Metabolism Research and Reviews, vol. 26, no. 4, pp. 306-318, 2010.
19. M. J. Reed, K. Meszaros, L. J. Entes et al., "A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat," Metabolism, vol. 49, no. 11, pp. 1390-1394, 2000.
20. K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, "Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening," Pharmacological Research, vol. 52, no. 4, pp. 313-320, 2005.
21. E. P. Davidson, L. J. Coppey, A. Holmes, B. Dake, and M. A. Yorek, "Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications," European Journal of Pharmacology, vol. 668, no. 3, pp. 497-506, 2011.
22. A. S. Al-Goblan, M. A. Al-Alfi, and M. Z. Khan, "Mechanism linking diabetes mellitus and obesity," Diabetes, Metabolic Syndrome and Obesity, vol. 7, pp. 587-591, 2014.
23. N. Esser, S. Legrand-Poels, J. Piette, A. J. Scheen, and N. Paquot, "Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes," Diabetes Research and Clinical Practice, vol. 105, no. 2, pp. 141-150, 2014.
24. U. J. Jung and M.-S. Choi, "Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease," International Journal of Molecular Sciences, vol. 15, no. 4, pp. 6184-6223, 2014.
25. M. Matsuda and I. Shimomura, "Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer," Obesity Research and Clinical Practice, vol. 7, no. 5, pp. e330-e341, 2013.
26. M. Cortez, J. R. Singleton, and A. G. Smith, "Glucose intolerance, metabolic syndrome, and neuropathy," in Handbook Clinical Neurology, vol. 126, pp. 109-122, 2014.
27. S. Divisova, E. Vlckova, M. Hnojcikova et al., "Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres," Journal of the Peripheral Nervous System, vol. 17, no. 3, pp. 341-350, 2012.
28. N. Papanas and D. Ziegler, "Prediabetic neuropathy: does it exist?" Current Diabetes Reports, vol. 12, no. 4, pp. 376-383, 2012.
29. N. Papanas, A. I. Vinik, and D. Ziegler, "Neuropathy in prediabetes: does the clock start ticking early?" Nature Reviews Endocrinology, vol. 7, no. 11, pp. 682-690, 2011.
30. L. J. Coppey, A. Holmes, E. P. Davidson, and M. A. Yorek, "Partial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic rat," Journal of Nutrition and Metabolism, vol. 2012, Article ID 950517, 8 pages, 2012.
31. K. K. Beiswenger, N. A. Calcutt, and A. P. Mizisin, "Epidermal nerve fiber quantification in the assessment of diabetic neuropathy," Acta Histochemica, vol. 110, no. 5, pp. 351-362, 2008.
32. E. P. Davidson, L. J. Coppey, B. Dake, and M. A. Yorek, "Effect of treatment of sprague dawley rats with AVE7688, enalapril, or candoxatril on diet-induced obesity," Journal of Obesity, vol. 2011, Article ID 686952, 9 pages, 2011.
33. J. L. D. M. Zeve, C. A. B. Tomaz, P. A. N. Nassif, J. H. Lima, L. R. Z. Sansana, and C. H. Zeve, "Obese patients with diabetes mellitus type 2 undergoing gastric bypass in Rouxen-Y: analysis of results and its influence in complications," Arquivos Brasileiros de Cirurgia Digestiva, vol. 26, pp. 47-52, 2013.
34. A. B. Crugeiras, M. C. Carreira, B. Cabia, S. Andrade, M. Amil, and F. F. Casanueva, "Leptin resistance in obesity: an epigenetic landscape," Life Sciences, 2015.
35. N. F. Sheard, "Moderate changes in weight and physical activity can prevent or delay the development of type 2 diabetes mellitus in susceptible individuals," Nutrition Reviews, vol. 61, no. 2, pp. 76-79, 2003.
36. J. P. Foreyt and W. S. Poston, "The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient," International Journal of Obesity, vol. 7, pp. S5-S11, 1999.
37. J. R. Singleton, R. L. Marcus, J. E. Jackson, M. K. Lessard, T. E. Graham, and A. G. Smith, "Exercise increases cutaneous nerve density in diabetic patients without neuropathy," Annals of Clinical and Translational Neurology, vol. 1, no. 10, pp. 844-849, 2014.
38. J. R. Singleton, R. L. Marcus, M. K. Lessard, J. E. Jackson, and A. G. Smith, "Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients," Annals of Neurology, vol. 77, no. 1, pp. 146-153, 2015.
39. S. Dixit, A. G. Maiya, and B. A. Shastry, "Effect of aerobic exercise on peripheral nerve functions of population with diabetic peripheral neuropathy in type 2 diabetes: a single blind, parallel group randomized controlled trial," Journal of Diabetes and its Complications, vol. 28, no. 3, pp. 332-339, 2014.
40. H. Y. Jin, K. A. Lee, and T. S. Park, "The effect of exercise on the peripheral nerve in streptozotocin (STZ)-induced diabetic rats," Endocrine, vol. 48, no. 3, pp. 826-833, 2015.
41. C. L. Oltman, E. P. Davidson, L. J. Coppey et al., "Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse," Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 64-74, 2008.
42. H. Shevalye, M. S. Yorek, L. J. Coppey et al., "Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes," Journal of Neurophysiology, 2015.